


Stellingen behorende bij dit proefschrift:

CLINICAL RESEARCH IN SOLID CANCERS

From biology to predictive and prognostic biomarkers

Debbie Germaine Joseph Robbrecht

1. TAS-119 has a favourable and remarkably distinct safety profile from other AurA inhibitors. (*this thesis*)
2. IL1RAP is overexpressed in a number of solid tumours and hematologic malignancies which makes it an attractive target for anticancer drug development. (*this thesis*)
3. Although the reported relationship between peak plasma concentration and neutropenia is not definitively established, the lower neutropenia rate with oral ModraDoc006/r as compared to intravenous docetaxel may be explained by an up to 10-fold lower peak plasma concentration of docetaxel with ModraDoc006/r. (*this thesis*)
4. The type of progression at baseline strongly predicts overall survival in men with metastatic castration resistant prostate cancer treated with first-line chemotherapy. (*this thesis*)
5. The modified Fast Aneuploidy Screening Test-Sequencing System (mFast-SeqS) provides a high-throughput, affordable, and robust assay to stratify metastatic urothelial cancer patients for their eligibility for pembrolizumab treatment. (*this thesis*)
6. All substances are poisons; there is none that is not a poison. The right dose differentiates a poison from a remedy. (*Paracelsus, 16th century*)
7. In order to avoid failures of anticancer agents in phase 3 trials, it is essential to answer the right questions during their very first phases of clinical development. (*Adapted from Mansinho et al, Annals of Oncology, 2019*)
8. Circulating cell-free DNA dynamics should be incorporated into oncologic treatment protocols in order to assess their added value in daily clinical practice. (*Adapted from statement in thesis F.M. de Man, 2019*)
9. The outcomes in patients with cancer stands to be improved by wider deployment of advanced prognostic and predictive biomarkers. However, development and use of these markers faces many challenges. (*Adapted from Horgan et al, Biomedicine Hub, 2020*)
10. Oncology drug development entails a large subsidy of altruism, time, and welfare from patients themselves (*Hutchinson et al, JAMA Netw Open, 2021*)
11. Seek beyond what we know (*Down to Earth – KELTEK *)